On the 7th November 2019 the largest medical cannabis register in Europe was announced from one of the UK’s leading medical bodies. Project TWENTY21 is led by Drug Science, a committee of scientists founded in 2010 to bring together leading drugs experts from a wide range of specialisms to carry out groundbreaking research into drug harms and effects. The teams vision is:

    To see a world where drug control is rational and evidence-based; where drug use is better informed and drug users are understood; where drugs are used to heal not harm.

    On that end, the registry will include 20,000 patients in the UK that will be given subsidized medical cannabis over a two-year period to create the largest body of evidence on cannabis in Europe.

    Medicinal cannabis was legalised in Britain last November but patients have been struggling to get access to the drug. Many doctors are reluctant to prescribe due to lack of guidance and training. The project will also support prescribers across the country to feel confident in providing medical cannabis to patients.

    AnnTWENTY21 is a registry, not a clinical trial.

    The study is backed by the Royal College of Psychiatrists

    The registry is also backed by the Royal College of Psychiatrists who have launched also a call for evidence from anyone with expertise and personal experience of medical cannabis and cannabis for recreational use to contribute to a Review by providing relevant evidence.

    Conditions treated

    In the first scale the project will focus on seven conditions in patients for whom alternative treatment has failed.

    • Anxiety disorder
    • Chronic pain
    • Epilepsy
    • Multiple sclerosis
    • Post-traumatic stress disorder
    • Substance use disorder (as a harm reduction strategy)
    • Tourette’s syndrome

    Furthermore, medical cannabis clinics will only accept patients who have attempted two different licensed medications to treat their condition, both of which must have proven to be ineffective.


    During this 5 step process patients will be navigated through the project on a seamless journey:

    1. Patients register
    2. Notification
    3. Referral from self or clinician
    4. Medical cannabis prescribed
    5. Drug Science follow-up


    Treatment will be provided at a network of clinics across the UK and remotely through telemedicine services. Drug Science is an independent charity that was established in 2010. It is dedicated to bringing together experts from different backgrounds for determining the positive and negative aspects of certain drugs.

    There are more than eight million people with disabling chronic pain in the UK and medical cannabis is still out of reach for them. Trials like Project Twenty21 could provide evidence for safely and effectively prescribing these medicines that has the potential to provide pain relief and other life-changing benefits for some of these patients.

    President of the British Pain Society, Dr Arun Bhaskar

    The project is expected to conclude in 2021. The registry data will be available for researchers to access and expand their research into medical cannabis.

    Share via
    Copy link